Ibrutinib for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Ibrutinib for COVID-19

1 study with 46 patients

Serious outcome risk

Ibrutinib

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Ibrutinib studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−9%

Mortality (1)−9%

RCTs (1)−9%

Late (1)−9%

00.511.5+

← Ibrutinib
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Sep 20 2022	Woyach et al., NCT04439006	Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
	10 patient ibrutinib late treatment RCT with results not reported over 4 years after completion.
Mar 24 2022	Coutre et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac104	Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study
	9% higher mortality (p=1), 9% lower hospital discharge (p=1), and 35% lower progression (p=0.7). RCT 46 hospitalized patients with severe COVID-19 showing no significant differences with ibrutinib treatment.